glp-1 receptor agonist type 1 diabetes randomized trial agonists in the treatment of 2 – state-of-the-art GLP-1 receptor agonists and next-generation
Description
Hainer V, Toplak H, Mitrakou A
[DOI] [PMC free article] [PubMed] [Google Scholar] 17
00203-5/asset/a8f69d17-d3be-493d-a403-9e1bd60f380c/main.assets/gr4_lrg.jpg)
Mol Metab 2022;63:101533.ArticlePubMedPMC 61
Endogenous hyperinsulinemia may cause weight gain and obesity [30], and treatment with insulin causes substantial weight gain, and may even increase cardiovascular risk [31]
